Kinaxo | GenomeWeb


This article originally ran on May 15 and has been updated to include additional comments from GlaxoSmithKline.
GlaxoSmithKline said today that it has entered an agreement to purchase chemical proteomics firm Cellzome for £61 million ($99 million).

By Adam Bonislawski
University of North Carolina researchers have developed a chemical proteomics approach to measure global kinase activity and used it to investigate drug resistance in triple-negative breast cancer.

The deal marks the first pharma alliance for Evotec since it acquired Kinaxo in mid-April in a deal worth up to $23 million.

Entitled "Proteome-wide quantification of small molecule binding to cellular target proteins," the patent encompasses the company's Cellular Target Profiling, KinAffinity, and Epigenetics Target Profiling services.

The agreement calls for Kinaxo to provide quantitative analyses of PTMs on a proteome-wide scale with the expectation that "such comprehensive analysis will gain valuable insights into cellular functions of potential drug targets," the company said in a statement.

In addition to biomarker discovery, Kinaxo's PhosphoScout technology will be used to assess the anti-cancer drug Nexavar's effects on cellular phosphorylation patterns.

Kinaxo Biotechnologies and Bayer Vital announced that they are collaborating to identify novel cancer treatment biomarkers.

New Products


Agilent Technologies, Bio-Rad, Bruker, Pressure BioScieces, Thermo Fisher Scientific, Pheonomenex, Kinaxo

In Nature this week: genetic history of HIV in the US, and more.

There are a few projects aimed at addressing the lack of diversity in genomic research, Technology Review reports.

A national assessment shows that US students lag in the sciences, but suggests that achievement gaps are narrowing.

Harvard's George Church discusses HGP-write with the Journal of the American Medical Association.